Piper Sandler sets a price target of $142 for NASDAQ:ABVX, indicating a potential increase of 27.95%.The "Strong Buy" rating is driven by positive phase 3 ABTECT induction data for obefazimod, highlighting its potential in the ulcerative colitis therapy market.Abivax plans significant milestones in 2026, including filing for New Drug Application (NDA) and Marketing Authorization Application (MAA) if trials remain positive.Abivax SA (NASDAQ:ABVX) is a biopharmaceutical company focused on developing therapies ...

Abivax Presents Third Quarter 2025 Financial Results Cash and cash equivalents of EUR 589.7 (as of September 30, 2025) with a cash runway into Q4 2027 PARIS, France, December 15, 2025, 10:05 p.m. CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announce ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Abivax SA’s (NASDAQ:ABVX) stock is trading higher on Wednesday.The stock reacted to market rumours that U.S. pharma giant Eli Lilly and Co (NYSE:LLY) could make an offer. • Abivax stock is charging ahead with explosive momentum. Check out ABVX shares here.The “share price movement is driven by speculation around a possible takeover,” Stifel analyst Damien Choplain told Reuters.Over the past six months, the Paris-based company’s stock has surged by over 1,500% as per data from Benzinga Pro.Abivax stock skyro ...

U.S. stocks were mixed, with the Nasdaq Composite falling more than 100 points on Wednesday.Shares of Daktronics, Inc. (NASDAQ:DAKT) rose sharply during Wednesday's session after the company reported better-than-expected quarterly financial results.Daktronics reported quarterly earnings of 35 cents per share which beat the analyst consensus estimate of 27 cents per share. The company reported quarterly sales of $229.253 million which beat the analyst consensus estimate of $214.077 million.Daktronics shares ...

法国生物技术公司Abivax(ABVX.US)盘初大涨超10%，报135.65美元，创历史新高。消息面上，市场猜 测礼来可能有意收购Abivax，礼来对此传闻表示：不对业务发展活动发表评论。此外，LifeSci Capital 维持对Abivax的"买入"评级，目标价为170美元。Abivax公司曾于7月报告obefazimod在溃疡性结肠炎治 疗中的三期临床试验积极结果。(格隆汇) ...

本文源自：格隆汇 法国生物技术公司Abivax(ABVX.US)盘前涨10.5%，报135.97美元。消息面上，市场猜测礼来可能有意 收购Abivax，礼来对此传闻表示：不对业务发展活动发表评论。Abivax公司曾于7月报告obefazimod在 溃疡性结肠炎治疗中的三期临床试验积极结果。 ...

法国生物技术公司Abivax(ABVX.US)盘前涨10.5%，报135.97美元。消息面上，市场猜测礼来可能有意 收购Abivax，礼来对此传闻表示：不对业务发展活动发表评论。Abivax公司曾于7月报告obefazimod在 溃疡性结肠炎治疗中的三期临床试验积极结果。(格隆汇) ...

智通财经APP获悉，法国生物科技公司Abivax(ABVX.US)周三在巴黎股市和美股盘前走高，此次有报道 指出，此番股价异动源于市场对减肥药巨头礼来(LLY.US)可能发起收购要约的猜测。 事实上，这家总部位于巴黎的企业早已不是首次卷入收购传闻。金融情报机构Betaville此前于9月和11 月两度发布关于Abivax可能被收购的"未经核实"市场猜测，均曾推动其美国存托凭证(ADR)价格上涨。 回溯今年7月，Abivax曾公布重磅利好：其每日一次口服的obefazimod，在两项治疗溃疡性结肠炎的Ⅲ 期临床试验中均达到主要终点，消息一出，公司股价随即迎来暴涨。 作为一家临床阶段生物科技企业，Abivax的核心在研产品obefazimod主要用于治疗溃疡性结肠炎等炎症 性疾病。截至发稿，该公司股价在巴黎股市上涨逾10%，对应市值攀升至约80亿欧元(折合93亿美元)， 较今年年初5亿欧元的估值实现大幅跃升。美股盘前，该股涨超9%。 "此番股价波动的核心驱动因素，是市场对于潜在收购交易的猜测，"Stifel分析师Damien Choplain表 示。 礼来对此回应称："我们不对业务发展活动发表评论。" ...

Core Viewpoint - Shares of French biotech company Abivax increased by 20% due to market speculation regarding a potential bid from U.S. pharmaceutical giant Eli Lilly [1] Company Summary - Abivax is a French biotech firm experiencing a significant rise in share price, attributed to rumors of interest from Eli Lilly [1] Industry Summary - The news highlights the potential for mergers and acquisitions within the biotech sector, particularly involving established pharmaceutical companies like Eli Lilly [1]